Tag Archives: Neuronex

Arrivo BioVentures Lands $49M to Fuel Hunt for New Drugs

Usually when a biotech company makes a large fundraising announcement, the cash is committed to taking a specific drug through clinical trials. Arrivo BioVentures has secured $49 million in capital to first find the drugs to develop. The approach is similar to what the Morrisville, NC-based company’s management team did with three previous biotech firms, […]

Posted in National blog main, New York blog main, Raleigh-Durham, Raleigh-Durham blog main, Raleigh-Durham top stories | Tagged , , , , , , , , , , , , , , , | Comments Off on Arrivo BioVentures Lands $49M to Fuel Hunt for New Drugs

Four Years After Neuronex Buyout, Acorda Dumps Epilepsy Drug

Back in 2012, Acorda Therapeutics bought a Morrisville, NC, company called Neuronex as part of a plan to branch out beyond its flagship multiple sclerosis drug dalfampridine (Ampyra). Unfortunately, the drug, a nasal spray form of the old seizure control drug diazepam, never lived up to expectations, leading Acorda today to shelve it altogether. Ardsley, […]

Posted in National blog main, New York, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories | Tagged , , , , , , , , , , , , , | Comments Off on Four Years After Neuronex Buyout, Acorda Dumps Epilepsy Drug

East Coast Biotech Roundup: Concert, Merrimack, Vertex, & More

A near-death experience for an IPO, new life for a cancer drug company, and plenty of clinical trial results dot the roundup this week. Those stories and more below. —Lexington, MA-based Concert Pharmaceuticals (NASDAQ: CNCE) may have priced its IPO at the top of its range earlier this year, but not without a fair bit […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Concert, Merrimack, Vertex, & More